Beyond Height Velocity: Longitudinal Impact of Long-Acting Growth Hormone on Body Mass Index in Pediatric Growth Hormone Deficiency
Posted inClinical Updates Diabetes & Endocrinology news Pediatrics

Beyond Height Velocity: Longitudinal Impact of Long-Acting Growth Hormone on Body Mass Index in Pediatric Growth Hormone Deficiency

This meta-analysis reveals that long-acting growth hormone (LAGH) is associated with a significant increase in BMI SD scores during the first year of treatment and upon switching from daily GH, suggesting a distinct metabolic profile compared to daily regimens.
Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis
Posted inClinical Updates news OB/GYN & Women's Health Orthopedics

Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis

This review analyzes the LIDA trial findings, demonstrating that an abbreviated 3-month romosozumab course followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially reducing costs and treatment burden.
Transitioning to Tubeless Automated Insulin Delivery: Clinical Insights from the RADIANT Trial and Contemporary Management of Type 1 Diabetes
Posted inClinical Updates Diabetes & Endocrinology news

Transitioning to Tubeless Automated Insulin Delivery: Clinical Insights from the RADIANT Trial and Contemporary Management of Type 1 Diabetes

This review synthesizes the landmark RADIANT trial findings, demonstrating the efficacy of transitioning patients from multiple daily injections to tubeless automated insulin delivery, while integrating broader evidence on genetic susceptibility and metabolic comorbidity management.